Revance Therapeutics | Driftsresultat

Operating Profit Lave om Dato
AbbVie USD 3.2B 914M 2023-12
ALKERMES USD 43.85M 195.34M 2023-09
Bristol-Myers Squibb USD 1.85B 473M 2023-12
Eli Lilly USD 2.39B 1.94B 2023-12
Merck USD -1933000000 7.68B 2023-12
Neurocrine Biosciences USD 141.2M 67.6M 2023-09
Pacira USD 33.17M 15.45M 2023-12
Supernus Pharmaceuticals USD -996000 9.13M 2023-12



Revance Therapeutics Driftsresultat - Aktuelle værdier, historiske data, prognoser, statistik, diagrammer og økonomisk kalender - Apr 2024.